CN107693519A - A kind of Lansoprazole tablet composition - Google Patents
A kind of Lansoprazole tablet composition Download PDFInfo
- Publication number
- CN107693519A CN107693519A CN201711126223.2A CN201711126223A CN107693519A CN 107693519 A CN107693519 A CN 107693519A CN 201711126223 A CN201711126223 A CN 201711126223A CN 107693519 A CN107693519 A CN 107693519A
- Authority
- CN
- China
- Prior art keywords
- lansoprazole
- tablet composition
- benzbromarone
- active component
- lansoprazole tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to field of medicaments, discloses Lansoprazole tablet composition, and the weight ratio of active component Lansoprazole and Benzbromarone contained by it is 1：35, and open Lansoprazole and Benzbromarone use in conjunction can significantly reduce experimental hyperuricemia mouse serum uric acid level, have treatment gout effect.
Description
Technical field
The present invention relates to pharmaceutical technology field, and in particular to a kind of Lansoprazole tablet composition.
Background technology
Lansoprazole (lansoprazole), alias Takepron, youth's rope that azoles, are a kind of chemistry of white crystalline powder
Product.Chemical name 2- [[[3- methyl -4- (2,2,2- trifluoro ethoxy) -2- pyridine radicals] methyl]-sulfinyl] -1H- benzos
Imidazoles, molecular formula C16H14F3N3O2S, molecular weight 369.36100.Levetiracetam is new gastric acid secretion inhibiting medicine
Thing, clinically it is mainly used in treating gastric ulcer, duodenal ulcer, reflux esophagitis, Zuo-Chinese mugwort (Zollinger-
Ellison) syndrome (gastrinoma).
Benzbromarone is benzofuran derivative, has and suppresses renal tubule in the resorption of uric acid thus reduction blood
Uric acid concentration.Oral easily to absorb, its metabolite is has acting type, and uric acid is 66.5% before medication in 24 hours blood after medication.
For treating gout.Adverse reaction mainly has：Suffer from diarrhoea, have a stomach upset, the gastrointestinal symptom such as nausea；Wheal, macula, flush,
The skin allergies such as itch；Dysfunction of liver and glutamic-oxalacetic transaminease, glutamic-pyruvic transaminase and alkaline phosphatase rise.
The diet of modern society people is based on the food of high-protein high-fat and high sugar.High-protein high-fat and high sugar
Because core former times acid content is higher in food, and uric acid is the product of core back of the body acid metabolic, therefore the dietary structure of modern society is more
Easily trigger uric acid content in human body too high, or even gout.
At present, prior art is not also on Lansoprazole and the report of Benzbromarone use in conjunction, typically without the two
Prevent or treat the report of gout after use in conjunction.
The content of the invention
Goal of the invention：In order to solve the above problems, the present inventor has been surprisingly found that in long-term clinical position, Lansoprazole
With Benzbromarone use in conjunction energy anti-hepatic fibrosis.
Technical scheme：The purpose of the present invention is realized by following scheme：
A kind of Lansoprazole tablet composition, the active component contained by it are made up of Lansoprazole, Benzbromarone.
The Lansoprazole tablet composition, the weight ratio of active component Lansoprazole and Benzbromarone contained by it is 1：3-
5。
The Lansoprazole tablet composition, the weight ratio of active component Lansoprazole and Benzbromarone contained by it is 1：4.
The Lansoprazole tablet composition, preparation method comprise the following steps：Lansoprazole, Benzbromarone, filler are taken,
Crush, be well mixed, adhesive granulation plus lubricant, tabletting.
The Lansoprazole tablet composition, in preparation method filler be dextrin, starch, one kind in microcrystalline cellulose or
A variety of, adhesive is pure water or ethanol, and lubricant is the one or more in talcum powder, superfine silica gel powder.
Application of the Lansoprazole tablet composition in anti-hepatic fibrosis medicine is prepared..
Above-mentioned Benzbromarone is produced by Chengdu De Site Bioisystech Co., Ltd.
Beneficial effect：Lansoprazole and Benzbromarone use in conjunction of the present invention can significantly reduce the hydroxyproline in hepatic tissue
Content and total lipid content, illustrate there is good therapeutic action to liver fibrosis.
Embodiment
Form by the following examples, the above of the present invention is described in further detail again, but should not be by this
The scope for being interpreted as the above-mentioned theme of the present invention is only limitted to following example, and all technologies for being realized based on the above of the present invention are equal
Belong to the scope of the present invention.
Embodiment 1：Lansoprazole 10g, Benzbromarone 30g, starch 20g are taken, is crushed, is well mixed, is made of suitable quantity of water viscous
Mixture prepares plus moderate lubrication agent talcum powder, tabletting.
Embodiment 2：Lansoprazole 10g, Benzbromarone 50g, dextrin 20g are taken, is crushed, is well mixed, is made of suitable quantity of water viscous
Mixture prepares plus moderate lubrication agent superfine silica gel powder, tabletting.
Embodiment 3：Lansoprazole 10g, Benzbromarone 40g, microcrystalline cellulose 20g are taken, is crushed, is well mixed, with appropriate
Water makees adhesive and prepares, adds moderate lubrication agent talcum powder, tabletting.
Embodiment 4：Lansoprazole 10g, microcrystalline cellulose 20g are taken, is crushed, is well mixed, adhesive system is done with suitable quantity of water
Standby plus moderate lubrication agent talcum powder, tabletting.
Embodiment 5：Benzbromarone 40g, microcrystalline cellulose 20g are taken, is crushed, is well mixed, adhesive system is done with suitable quantity of water
Standby plus moderate lubrication agent talcum powder, tabletting.
Embodiment 6：The pharmacological research of present invention treatment gout
Tested material：Prepared by the preparation method of above-described embodiment 3,4,5.
Experimental animal：NIH mouse, purchased from Medical University Of Anhui's Experimental Animal Center.
Instrument and equipment：BECKMAN CX9ALX full automatic biochemical apparatus.
Experimental method：NIH mouse 50 are taken, male and female half and half, body weight 18-22g, are randomly divided into 5 groups：Distilled water group, secondary Huang
Purine+distilled water group, 3 groups of hypoxanthine+1g/kg embodiments, 4 groups of hypoxanthine+1g/kg embodiments, hypoxanthine+1g/kg
5 groups of embodiment.It is administered orally daily per mouse, continuous 4 days.After last dose 1 hour, remaining each group animal is equal in addition to distilled water group
Intraperitoneal injection of hypoxanthine lg/kg causes the capacity physiological saline such as Studies on Animal Models of Hyperuricemic Mice, distilled water group injection.After injection
30 minutes, each group animal plucked eyeball and takes blood, 3000RPM centrifugation 15min, takes serum to survey blood uric acid value.
Experimental result：3 groups of the embodiment of Lansoprazole and Benzbromarone use in conjunction can reduce experimental hyperuricemia
Mouse serum uric acid level,
Influence (x ± SD, μm ol/ml, n=10) to experimental hyperuricemia mouse serum uric acid level
* compared with hypoxanthine model group, P ＜ 0.05, * * are compared with hypoxanthine model group, P ＜ 0.01；
＆ is compared with embodiment 4, and the , ＆＆ of P ＜ 0.05 are compared with embodiment 4, P ＜ 0.01；
$ is compared with embodiment 5, and the , $$ of P ＜ 0.05 are compared with embodiment 5, P ＜ 0.01.
Upper table shows that it is small that Lansoprazole and Benzbromarone use in conjunction of the present invention can significantly reduce experimental hyperuricemia
Mouse serum uric acid level, and effect is better than exclusive use Lansoprazole and Benzbromarone is used alone, and illustrates Lansoprazole and benzene
The grand use in conjunction of bromine horse has synergistic therapeutic action to gout.
Claims (6)
1. a kind of Lansoprazole tablet composition, it is characterised in that the active component contained by it is by Lansoprazole, Benzbromarone group
Into.
2. Lansoprazole tablet composition as claimed in claim 1, it is characterised in that active component Lansoprazole and benzene contained by it
Bromine Ma Long weight ratio is 1：3-5.
3. Lansoprazole tablet composition as claimed in claim 1, it is characterised in that active component Lansoprazole and benzene contained by it
Bromine Ma Long weight ratio is 1：4.
4. Lansoprazole tablet composition as claimed in claim 1, it is characterised in that preparation method comprises the following steps：Take blue rope
Azoles, Benzbromarone, filler are drawn, is crushed, is well mixed, adhesive granulation plus lubricant, tabletting.
5. Lansoprazole tablet composition as claimed in claim 4, it is characterised in that in preparation method filler be dextrin, starch,
One or more in microcrystalline cellulose, adhesive are pure water or ethanol, lubricant be talcum powder, one kind in superfine silica gel powder or
It is a variety of.
6. Lansoprazole tablet composition as claimed in claim 1 is preparing the application in treating gout medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711126223.2A CN107693519A (en) | 2017-11-15 | 2017-11-15 | A kind of Lansoprazole tablet composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711126223.2A CN107693519A (en) | 2017-11-15 | 2017-11-15 | A kind of Lansoprazole tablet composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107693519A true CN107693519A (en) | 2018-02-16 |
Family
ID=61179523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711126223.2A Withdrawn CN107693519A (en) | 2017-11-15 | 2017-11-15 | A kind of Lansoprazole tablet composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107693519A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110522752A (en) * | 2019-08-19 | 2019-12-03 | 庹必光 | Application of the Pantoprazole in the drug of preparation prevention and treatment liver fibrosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101646440A (en) * | 2007-01-19 | 2010-02-10 | 武田制药北美公司 | Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents |
| CN101658519A (en) * | 2008-08-26 | 2010-03-03 | 天津泰普药品科技发展有限公司 | Medicinal composition for treating hyperuricemia |
-
2017
- 2017-11-15 CN CN201711126223.2A patent/CN107693519A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101646440A (en) * | 2007-01-19 | 2010-02-10 | 武田制药北美公司 | Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents |
| CN101658519A (en) * | 2008-08-26 | 2010-03-03 | 天津泰普药品科技发展有限公司 | Medicinal composition for treating hyperuricemia |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110522752A (en) * | 2019-08-19 | 2019-12-03 | 庹必光 | Application of the Pantoprazole in the drug of preparation prevention and treatment liver fibrosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070264367A1 (en) | Composition containing an extract of shisandrae fructus for preventing and treating metabolic bone diseases, oxidative stress-induced diseases and inflammatory diseases | |
| JP2005508976A (en) | Methods and compositions for promoting repair and regeneration of mucosal tissue in the gastrointestinal tract | |
| CN103717219B (en) | Left ventricular diastolic function improving agent | |
| CN1621041A (en) | Pharmaceutical composition with pain easing function | |
| CN103181552A (en) | Health care food for regulating blood lipid and preparation method thereof | |
| CN103083557A (en) | Traditional Chinese medicine composition with functions of reducing blood pressure and blood fat | |
| TW200946142A (en) | Tablet | |
| WO2006118212A1 (en) | Agent for preventing and treating pancreatitis | |
| CN107693519A (en) | A kind of Lansoprazole tablet composition | |
| CN107648479A (en) | A kind of Chinese prescription and its product for being used to treat hypertension | |
| CN103446456B (en) | Treatment hypertension and the method for hyperlipidaemic conditions and the Chinese medicine composition of use | |
| CN102641357B (en) | Medicament for treating hypertension and preparation method thereof | |
| JPS62207212A (en) | Antiallergic agent | |
| CN104800690B (en) | A kind of Chinese medicine of anti-trioxypurine and preparation method thereof | |
| CN101317842A (en) | Treating uses of imidazole-5-carboxylic acid derivant | |
| CN1321639C (en) | Arthritis therapeutic drug | |
| CN114099565A (en) | Pharmaceutical composition for treating frequent nocturia and preparation method thereof | |
| CN103356669B (en) | Houttuynoid A treats in preparation or prevents the application in the medicine of acute heart failure | |
| CN102631397A (en) | Traditional Chinese medicine composition for improving cerebral blood circulation and preparation method thereof | |
| CN101524353A (en) | Oral anti-allergy compound pharmaceutical composition | |
| CN102058786B (en) | Chinese medicine composition for treating hypertension and preparation method thereof | |
| CN105616430B (en) | A kind of pharmaceutical composition of the treatment fatty liver containing Glucosamine | |
| CN1275590C (en) | Dispersion tablet containing ginkgo leaf extract | |
| CN112574290A (en) | Goat keratin, preparation method thereof, pharmaceutical composition thereof and application thereof | |
| CN102552481A (en) | Traditional Chinese medicinal composition with effects of smoothing collaterals and lowering blood pressure and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180216 |
|
| WW01 | Invention patent application withdrawn after publication |